Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

Article Tools

• Email

  Thank you for your interest in spreading the word about Science Immunology.

  NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

  Your Email

  Your Name

  Send To

  Enter multiple addresses on separate lines or separate them with commas.

  You are going to email the following Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

  Message Subject (Your Name) has forwarded a page to you from Science Immunology

  Message Body (Your Name) thought you would like to see this page from the Science Immunology web site.

  Your Personal Message

  CAPTCHA

  This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

  Send Message
• Download Powerpoint
• Print
• Alerts

  Please log in to add an alert for this article.

  Log In with your AAAS ID

  Sign In to Email Alerts with your Email Address

  Email

  Log in
• Citation tools

  Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

  By Zhida Liu, Chuanhui Han, Chunbo Dong, Aijun Shen, Eric Hsu, Zhenhua Ren, Changzheng Lu, Longchao Liu, Anli Zhang, Casey Timmerman, Yang Pu, Yang Wang, Mingyi Chen, Jian Qiao, Yang-Xin Fu

  Science Immunology09 Aug 2019

  Proper dosing and timing of EGFR TKI can trigger antitumor T cell responses and potentiate anti–PD-L1 immunotherapy.

  • Supplementary Materials

  Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
• Share

  Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

  By Zhida Liu, Chuanhui Han, Chunbo Dong, Aijun Shen, Eric Hsu, Zhenhua Ren, Changzheng Lu, Longchao Liu, Anli Zhang, Casey Timmerman, Yang Pu, Yang Wang, Mingyi Chen, Jian Qiao, Yang-Xin Fu

  Science Immunology09 Aug 2019

  Proper dosing and timing of EGFR TKI can trigger antitumor T cell responses and potentiate anti–PD-L1 immunotherapy.

  • Supplementary Materials

  Share This Article: Copy